

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



ELSEVIER

Journal of
**controlled
release**

Journal of Controlled Release 50 (1998) 79–92

Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor

Masayuki Yokoyama^{a,d}, Shigeto Fukushima^b, Ryuji Uehara^b, Kazuya Okamoto^b,
Kazunori Kataoka^{c,d,*}, Yasuhisa Sakurai^{a,d}, Teruo Okano^{a,d,*}

^a*Institute of Biomedical Engineering, Tokyo Women's Medical College, Kawada-cho, 8-1, Shinjuku-ku, Tokyo 162, Japan*

^b*Nippon Kayaku Co. Ltd., Iwahana 219, Takasaki-shi, Gunma 370-12, Japan*

^c*Department of Materials Science and Technology, Faculty of Industrial Science and Technology, Science University of Tokyo, Yamazaki 2641, Noda-shi, Chiba 278, Japan*

^d*International Center for Biomaterials Science (ICBS), in Research Institute for Biosciences, Science University of Tokyo, Yamazaki 2669, Noda-shi, Chiba 278, Japan*

Received 29 January 1997; accepted 30 May 1997

Abstract

An anticancer drug adriamycin (ADR) was incorporated into polymeric micelles forming from poly(ethylene glycol)-poly(aspartic acid) block copolymer by chemical conjugation and physical entrapment. Structural stability of the polymeric micelles was found to be dependent on both the contents of chemically conjugated and physically entrapped ADR. The polymeric micelle with high contents of the chemically conjugated ADR and the physically entrapped ADR expressed very high in vivo antitumor activity against murine C 26 tumor, while the polymeric micelle with only the chemically conjugated ADR showed negligible in vivo activity. This indicates that the physically entrapped ADR played a major role in antitumor activity in vivo. For the polymeric micelle with the high ADR contents, it was found that a dimer of adriamycin molecules formed and that this dimer was physically entrapped in the inner core of the micelle as well as intact ADR. © 1998 Elsevier Science B.V.

Keywords: Polymeric micelles; Stability; Anticancer drug; Adriamycin; Dimer

*Corresponding authors.

Abbreviations: ADR, adriamycin; ADR-HCl, adriamycin hydrochloride; DAU, daunomycin; N-Ac ADR, N-acetyl adriamycin; N-Ac DAU, N-acetyl daunomycin; EDC-HCl, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride; Asp, aspartic acid; PEG, poly(ethylene glycol); P(Asp), poly(aspartic acid); PEG-P(Asp), poly(ethylene glycol)-poly(aspartic acid) block copolymer; PEG-P(Asp(ADR)), adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer; HPLC, high-performance Liquid phase Chromatography; GPC, gel-permeation chromatography; DMF, N,N-dimethylformamide

1. Introduction

Drug delivery systems with long-circulating characteristics [1] in the bloodstream have caught much attention not only for chemo-therapeutic purposes [2] but also for diagnostic imaging. Delivery systems based on liposomes [3,4], microspheres [5], and polymeric micelles [6–9] have been studied for these purposes. Although polymeric micelle systems

have only several years' history of research for in vivo applications [10,11], significant enhancement of in vivo activity of an anticancer drug was obtained [6,12]. As compared with other types of carrier systems, the polymeric micelle systems possess several benefits [13,14] including the following important two characteristics. The first characteristic is wide applicability of the polymeric micelle systems to drugs, since drugs can be incorporated into the micelles both by chemical conjugation and physical entrapment. Particularly, physical entrapment utilizing hydrophobic interactions can be applied to many kinds of drugs [15] because most drugs contain hydrophobic moiety(ies) in their chemical structures. The second characteristic is size of polymeric micelles, which is in a diameter range approximately from 20 to 60 nm. This range of diameter is smaller than obtainable diameters of liposomes and micro(nano)spheres with considerable stability. The smaller carrier systems are expected to show the higher vascular permeability at target sites by diffusion mechanism. Furthermore, the diameter range of the polymeric micelle systems is considered to be appropriate to evade renal excretion and non-specific capture by the reticuloendothelial systems.

In our previous papers having reported high in vivo antitumor activities [6,12], a ratio between the chemically conjugated and physically entrapped ADR was not determined [16], and considerable amounts of adriamycin derivatives formed and were incorporated in the micelles. Our recent paper reported an improved ADR incorporation method which can determine this ratio and reduce amounts of adriamycin derivatives as impurities [17]. In this paper, the ADR incorporated in the inner core was quantitatively measured using the improved synthetic method, and effects of the ADR contents (both by chemical conjugation and physical entrapment) on micelle stability and in vivo antitumor activity were analyzed. By these analyses, a strategy in designing polymeric micelles for anticancer drug delivery was obtained.

2. Experimental part

2.1. Materials

Adriamycin hydrochloride (ADR·HCl) was pur-

chased from Mercian Corp., Japan. Other chemicals were of reagent grade and were used as purchased.

2.2. Chemical conjugation and physical entrapment of adriamycin to block copolymer

Procedures for chemical conjugation and physical entrapment of adriamycin (ADR) into polymeric micelles were based on a reference [17] with some modifications.

2.2.1. Chemical conjugation of ADR to block copolymer

Synthesis of poly(ethylene glycol)-poly(aspartic acid) block copolymer [PEG-P(Asp)] was reported in a reference [16]. Molecular weight of the poly(ethylene glycol) (PEG) chain and the poly(aspartic acid) (P(Asp)) chain was 12 000 and 2100, respectively. The content of the β -amide form of the aspartic acid residues was found ca. 75 mol.% (x:y=1:3 in Fig. 1). PEG-P(Asp) was dissolved in N,N-dimethylformamide (DMF), and adriamycin hydrochloride (ADR·HCl) and triethylamine (1.3 mol. equivalents to ADR) were consecutively added to the block copolymer solution. The mixture was cooled to 0°C, and the conjugation reaction was initiated by an addition of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC·HCl). Four hours following the reaction at 0°C with stirring, EDC·HCl was again added. Twenty hours after the second addition of EDC·HCl, the reaction mixture was dialyzed with a Spectrapor 2 dialysis membrane, followed by ultrafiltration using an Amicon ultrafiltration membrane PM 30 (MWCO=30 000) in distilled water. Details of the dialysis conditions are summarized in Table 1. Content of the chemically conjugated ADR in PEG-P(Asp(ADR)) with respect to the aspartic acid residues was determined by measuring an amount of unreacted ADR in the reaction mixture by reversed-phase chromatography. By subtracting this amount from that of the added ADR as a substrate, an amount of the conjugated ADR was obtained.

2.2.2. Physical entrapment of ADR into PEG-P(Asp(ADR))

The ADR-conjugated block copolymer [(PEG-P(Asp(ADR))) solution obtained above was dialyzed against DMF using a Spectrapor 2 dialysis mem-

brane for 3 h. / added by 3.0 / run 3, distilled / P(Asp(ADR)) s / ADR solution, / temperature. Th / distilled water / brane. Details / summarized in / entrapped ADR / chromatography / (physically ent

Table 1
Chemical conjugation

Run	ADR·HCl (mg)
A	700.7
B	311.2

^aWith respect to A

^bDialysis was again

a→(b)→c.

^cOut of the total A

n. Other chemicals
used as purchased.

Physical entrapment

ation and physical
(R) into polymeric
ce [17] with some

ADR to block

nycol)-poly(aspartic
p)) was reported in
light of the poly-
d the poly(aspartic
and 2100, respec-
nide form of the
a. 75 mol.% (x:y=
dissolved in N,N-
adriamycin hydro-
amine (1.3 mol.
tively added to the
ture was cooled to
was initiated by an
aminopropyl) car-
HCl). Four hours
stirring, EDC·HCl
after the second
ion mixture was
dialysis membrane,
n Amicon ultrafil-
D=30 000) in dis-
sis conditions are
of the chemically
ADR)) with respect
as determined by
ted ADR in the
e chromatography.
that of the added
of the conjugated

R into PEG-

opolymer [(PEG-
ove was dialyzed
2 dialysis mem-




Fig. 1. Preparation of polymeric micelle.

brane for 3 h. ADR·HCl was dissolved in DMF and added by 3.0 mol. equivalents of triethylamine. In run 3, distilled water was further added. The PEG-P(Asp(ADR)) solution in DMF was added to the ADR solution, and this mixture was stirred at room temperature. Then, the mixture was dialyzed against distilled water using a Spectrapor 2 dialysis membrane. Details of the entrapment conditions are summarized in Table 2. An amount of the physically entrapped ADR was determined by reversed-phase chromatography, and the total amount of ADR (physically entrapped ADR+chemically conjugated

ADR) was obtained by measuring absorption at 485 nm in distilled water.

2.3. General procedures

HPLC measurements were done at a flow-rate of 1.0 ml/min at 40°C. Detection was performed by absorption at 485 nm.

Reversed-phase chromatography was carried out with a Waters μ Bondasphere 5 μ C4-100Å column (3.9 mm×15 cm, Nihon Waters, Tokyo, Japan) with 20 μ l of samples at a concentration of 200 μ g

Table 1
Chemical conjugation of ADR to PEG-P(Asp) block copolymer

Run	ADR·HCl (mg)	PEG-P(Asp) (mg)	ADR Asp unit (molar ratio)	DMC (ml)	EDC·HCl (mg)	Ratio of conjugated ADR ^a	Dialysis (h) ^b			Residual free ADR in micelle (%)
							a	b	c	
A	700.7	1130	0.80	77	461+463	0.63	22	—	2	0.6
B	311.2	890	0.45	61	454+453	0.41	2	1	1	0.0

^aWith respect to Asp units.

^bDialysis was against; a: 3 vol.% acetic acid in methanol, b: 1 vol.% acetic acid in distilled water, c: distilled water in the order of a→(b)→c.

^cOut of the total ADR.

follows. Acetic acid (3 ml) was dissolved in 5 ml of DMF and added by 10 mg of EDC-HCl, followed by incubation at room temperature for 30 min. ADR-HCl or DAU-HCl (10 mg) was dissolved in 5 ml of DMF and added by 2 mg of triethylamine. This solution was mixed with the acetic acid/EDC-HCl solution, and this mixture was stirred at 35°C for 24 h. Complete conversion of ADR/DAU to N-acetyl ADR/DAU was confirmed by HPLC.

2.4.3. NMR measurements of a compound after reduction and acid-hydrolysis

The compound of the third peak was obtained as described in Section 2.4.1, and this reaction mixture was added by 2 mg of NaBH_3CN and stirred at room temperature for 4 h. Then, the reaction mixture was added by 100 μl of HCl (11.8 M), and stirred at room temperature for 24 h. Purification of a product which showed absorbance at 485 nm was carried out by HPLC twice, in the conditions described below (Section 2.4.4) in the first run and in the conditions described above (general procedure) in the second run. The product was applied to SepPakC18. Then, the product was eluted with methanol. Methanol was evaporated, and the residual product was dissolved in DMSO-d_6 containing a small amount of DCl. Measurements were carried out using a JNM- α 400 spectrometer (JEOL, Tokyo, Japan).

2.4.4. HPLC analysis

Conditions of HPLC analysis were as follows; column: Waters μ -Bondasphere C_4 (5 μ , 300 Å), flow: 0.8 ml/min, elution: gradient of (a) 0.05% IPCC-MS7 (an ionpair reagent, GL Sciences, Tokyo, Japan) + 0.01% trifluoroacetic acid and (b) CH_3CN , and gradient is shown in Fig. 5a.

2.4.5. Mass spectroscopy

ESI-mass spectroscopic measurements were done using a Quattro II mass spectrometer (Micromass Ltd.).

2.5. In vivo antitumor activity

Antitumor activity against a solid tumor of polymeric micelles run A, 1, 2, and 3 and free ADR was evaluated with mouse colon adenocarcinoma 26 (C 26). C 26 cells (1×10^5 cells in 0.2 ml of 0.9% NaCl

solution) were transplanted into CDF1 female mice (6 weeks old) subcutaneously on day 0, and drug injection started on day 7 when tumor volume reached approximately 100 mm^3 . Drug was injected into a tail vein with a schedule of q4d \times 3 (on day 7, 11, and 15) in volume of 0.1 ml/10 g body weight. Six mice were included in one group except 12 mice for the control. The mortality was monitored daily, and tumor volume was measured at a few days interval. Tumor volume was calculated as follows: $\text{volume} = 1/2LW^2$; L is long diameter and W is short diameter. Statistical analysis was done on day 10 after the first drug injection using Dunnett's method.

2.6. In vitro cytotoxicity

In vitro cytotoxic activity of polymeric micelles run A, 1, 2, and 3 and free ADR were assayed against P 388D₁ mouse leukemia cells. P 388D₁ cells were incubated with serially diluted drugs (two-fold steps) in 100 μl of RPMI 1640 medium (containing 10% of fetal calf serum and 50 unit/l of penicillin and 50 $\mu\text{g/l}$ of streptomycin) with a Multiwell™ tissue culture plate (96-well) of Falcon 3047 for 24 h or 72 h in 5% CO_2 at 37°C. After the incubation for the defined period, cell viability was determined by MTT assay [18] to obtain the IC_{50} value.

3. Results

3.1. Chemical conjugation and physical entrapment of ADR

As summarized in Table 1, two adriamycin-block copolymer conjugates [PEG-P(Asp(ADR))] were synthesized of 63 mol.% and 41 mol.% substitution of aspartic acid (Asp) residues of the block copolymer with adriamycin (ADR) for run A and run B, respectively. Immediately after the conjugation reaction, 17 mol.% and 4 mol.% of ADR with respect to the Asp residues remained unconjugated for run A and run B, respectively. These unconjugated ADR were efficiently removed by dialysis against methanol containing 3% acetic acid (and 1% acetic acid aqueous solution for run B). As a result, less than 1% of the physically entrapped ADR out of

the total ADR (physically entrapped+chemically conjugated) remained in the polymeric micelles, as shown in reversed-phase chromatograms of Fig. 2 a and b; no or a very small peak of unconjugated ADR was seen at 7.3 min, while the conjugated ADR (PEG-P(Asp(ADR))) eluted as a broad peak with a peak top around 11.5 min.

ADR was successfully entrapped by physical manner into polymeric micelles forming from PEG-P(Asp(ADR)) as summarized in Table 2. In run 1 and 2, ADR was mixed with PEG-P(Asp(ADR)) in almost the same amount as that of the chemically conjugated ADR of PEG-P(Asp(ADR)), considerable amounts of ADR were physically entrapped in the micelles. This entrapment efficiency was dependent on the content of the chemically conjugated ADR in PEG-P(Asp(ADR)). In comparison between run 1 and run 2, more than double content of the physically entrapped ADR was obtained by using PEG-P(Asp(ADR)) run A, which had the higher content of the chemically conjugated ADR. This shows that non-covalent interactions between the chemically conjugated ADR and the added ADR preferentially occurred in the more concentrated atmosphere of the chemically conjugated ADR. Slightly higher physical entrapment (10.4%) was obtained in run 3 by mixing the substrates in a mixture of DMF and distilled water for a shorter period. For run 1, a new peak appeared at 10.4 min in a reversed-phase chromatogram. Characterization of this third peak at 10.4 min is described in a later part.

All five samples (run A, B, and 1-3) were observed to form micellar structures by polymeric micelle peaks eluting near the gel-exclusion of the column. Elution volumes from 4.4 to 5.3 ml correspond to much larger molecular weights than those of the ADR-block copolymer conjugates (M.W.: run A; 20 200, run B; 18 000). However, precise peak positions differed among them. Delay in elution is considered to result from some interactions of the polymeric micelles with gel of the column. In comparison between Fig. 3a and b, a peak at the larger elution volume was seen for PEG-P(Asp(ADR)) with the lower content of the chemical conjugated ADR. This indicates that the polymeric micelle forming from PEG-P(Asp(ADR)) run B interacted with gel in the column more strongly than the micelle from run A probably due to looser packing of the hydrophobic inner core of run B.




Fig. 3. Gel-filtration chromatograms of polymeric micelles. (a) run A, (b) run B, (c) run 1, (d) run 2, and (e) run 3. Column; Asahipak GS-520 H column, eluent; 0.1 M phosphate buffered solution (pH 7.4), sample; 100 μ l at a concentration of 20 μ g equivalent ADR/ml.

Thus, the content of the chemically conjugated ADR was found to influence stability of the micellar structures, and the stability of the micellar structure could be relatively evaluated by this gel-exclusion chromatography. By physical entrapment of ADR into the polymeric micelles, micelle peaks were observed to shift to smaller elution volumes for both PEG-P(Asp(ADR)) run A and B. Elution volume shifted from 4.6 ml (Fig. 3a) to 4.4 ml (Fig. 3c) for run A, and from 5.3 ml (Fig. 3b) to 4.8 ml (Fig. 3d and e) for run B. These results show that stability of the micellar structure increased by additions of the physically entrapped ADR probably due to increased hydrophobic interactions inside the inner cores of the micelles. These all results indicate that both the contents of the chemically conjugated ADR and physically entrapped ADR influenced the micelle stability measured by gel-filtration chromatography as well as chain lengths of the two segments of the block copolymer did in our preceding paper [19].

3.2. Identification of chemical structure of the third peak of Fig. 2c


In a reversed-phase chromatogram of run 1, the

third peak other than the chemically conjugated ADR at 10.4 ml in the reversed-phase chromatogram was identified as the chemical structure of the third peak. To separate the conjugated ADR pair reagent, C trifluoroacetic acid, the third peak was collected and analyzed. Molecular weight of the third peak was 1067.3. This was a dimer (derivatized compound) was also triethylamine in peak was identified following experiments.



- 1) When this (vol.) mixture of CH_3CN at room temperature was added to amounts of ADR, a reversed-phase peak at 485 nm. The linkage was identified.
- 2) ADR and

Table 3
Number of product
Substrate 2

ADR
N-Ac ADR
1) N-AcADR: N-acetyl



- 2) Reaction condition followed by addition



meric micelles. (a) run
3. Column; Asahipak
buffered solution (pH
of 20 µg equivalent

conjugated ADR
of the micellar
micellar structure
this gel-exclusion
rapment of ADR
elle peaks were
volumes for both
Elution volume
4 ml (Fig. 3c) for
o 4.8 ml (Fig. 3d
w that stability of
additions of the
y due to increased
inner cores of the
te that both the
gated ADR and
nced the micelle
chromatography
segments of the
ing paper [19].

cture of the

am of run 1, the

third peak other than intact ADR (7.3 ml) and the chemically conjugated ADR (11.5 ml) was observed at 10.4 ml in elution volume. In order to identify a chemical structure of this third peak, conditions of the reversed-phase chromatography were optimized to separate the third peak from the chemically conjugated ADR. When 0.05% IPCC-MS7 (an ion-pair reagent, GL Sciences, Tokyo, Japan) +0.01% trifluoroacetic acid in distilled water was used as one component of gradient eluent on behalf of 1% acetic acid, the third peak was separated from the other two peaks, as shown in Fig. 5a. This third peak was collected and analyzed by ESI-mass-spectroscopy. Molecular weight of this peak was revealed to be 1067.3. This value implies that this third peak was a dimer (derivative) of ADR molecules. This compound was also obtained by mixing ADR·HCl and triethylamine in DMF. The chemical structure of this peak was identified as shown in Fig. 4 by the following experimental results.


1) When this compound was incubated in a 30:70 (vol.) mixture of 1% acetic acid aqueous solution and CH₃CN at room temperature for 3 days, this compound was observed to change into equivalent amounts of ADR and the other compound in a reversed-phase chromatogram detected by adsorption at 485 nm. This result indicates that an acid-labile linkage was included in this compound.

2) ADR and 3 adriamycin analogues were mixed

Table 3
Number of products from adriamycin and its derivatives

Substrate 2	Substrate 1			
	ADR	N-Ac ADR	N-Ac DAU	DAU
ADR	1	2	1	2
N-Ac ADR	2	0	0	1

1) N-AcADR: N-acetyl adriamycin, DAU: daunomycin, and N-Ac DAU: N-acetyl daunomycin.



	R ₁	R ₂
ADR	OH	H
N-Ac ADR	OH	COCH ₃
DAU	H	H
N-Ac DAU	H	COCH ₃

2) Reaction conditions; One milliliter solution of substrate 1 (2 mg/ml) in DMF was mixed with substrate 2 solution (2 mg/ml) in DMF, followed by additions of 5 mg of triethylamine and 1 ml of water. This reaction mixture was incubated at room temperature for 5 h.




Fig. 4. Chemical structure of the third peak of Fig. 2(c).

in DMF with an addition of triethylamine, the number of products was dependent on combinations as summarized in Table 3. These numbers can be understood by the hypothesis that the products were obtained by reactions between a primary amino group (of ADR or daunomycin (DAU)) and a reactive carbonyl group of ADR or N-acetyl adriamycin.

3) This compound was treated with NaBH₃CN, followed by treatment with HCl. NMR spectrum of the product was measured in DMSO-d₆ containing a small amount of DCl. As shown in Fig. 5b–d, this




Fig. 5. Identification of the third peak of Fig. 2(c). (a) reversed-phase chromatogram; column: Waters μ -Bondasphere C₄ (5 μ , 300 Å), flow: 0.8 ml/min, elution: gradient of 0.05% IPCC-MS7 (an ionpair reagent)+0.01% trifluoroacetic acid and CH₃CN, gradient profile is shown in the figure. (b) ¹H-NMR spectrum, (c) COSY spectrum, and (d) CH COSY spectrum of the third peak after treatments with NaBH₄CN and HCl.





Fig. 5. (continued)

(5 μ , 300 Å), flow:
 at profile is shown in
 with NaBH₄CN and

product contained two protons at 3.50 ppm and 3.77 ppm, which were coupled with each other in COSY spectrum (Fig. 5c) and coupled with carbon at 61.8 ppm that was assigned as a methylene next to a carbonyl and a secondary amine in CH COSY spectrum (Fig. 5d). This product also contained a carbonyl carbon at 190.3 ppm, that is other than a carbonyl carbon of adriamycin molecule. From these results, it was elucidated that this compound contained $-\text{COCH}_2\text{NH}-$ after treatments with NaBH_3CN and HCl.

3.3. In vivo antitumor activity

Fig. 6 shows in vivo antitumor activities against C 26 tumor. Relative tumor volume from the day of the first intravenous injection is logarithmically plotted. In Fig. 6a, intact adriamycin showed significant inhibition effect on tumor growth only at the maximum tolerated dose (10 mg/kg, $p < 0.15$ on day 10). A higher dose (20 mg/kg) resulted in toxic deaths, and a lower dose (5 mg/kg) did not show significant tumor growth inhibition. One composition of the polymeric micelle (run 1) showed significant antitumor effect at a wider dose range than that of intact ADR, as shown in Fig. 6c. The polymeric micelle run 1 showed significant reduction of tumor volume at 2 doses; 50 mg total ADR/kg per day $p < 0.05$ on day 10 after the first injection, 25 mg total ADR/kg per day $p < 0.1$ on day 10 (total ADR means the chemically conjugated plus physically entrapped ADR). At this maximum tolerated dose (50 mg/kg), tumor completely disappeared in 2 mice out of 6. Such obtained high activity was at the same level of the polymeric micelle that was prepared by the old preparation method [6]. In Fig. 4b, no significant antitumor effect was observed for run A which lacked the physically entrapped ADR but had the same amount of the chemically conjugated ADR as that of run 1. This comparison indicates that the physically entrapped ADR was required to express significant antitumor effects against C 26 tumor. The other two compositions of micelles (run 2 and 3) with the lower amount of the chemically conjugated ADR did not express any significant antitumor activity, even though run 2 and run 3 at a dose of 50 mg/kg contained almost the same amount of the physically entrapped ADR as that of run 1 at a dose

of 25 mg/kg. These results indicate that antitumor activity was dependent on the ADR contents of the polymeric micelles.

3.4. In vitro antitumor activity

Cytotoxic activity of the polymeric micelles against P388D1 mouse leukemia cells are summarized in Table 4, where IC_{50} values are shown by the total (chemically conjugated+physically entrapped) ADR. All the polymeric micelle samples expressed incubation time-dependent cytotoxicity, and their IC_{50} values were much larger those of intact ADR both for 24 and 72 h incubation. When these values are multiplied with ratios of the physically entrapped ADR in the total ADR, the multiplied values are almost the same as with those of intact ADR: values between 0.16 and 0.19 are obtained in the three micelle samples for 24 h except run A (IC_{50} of intact ADR was 0.17) and values from 0.0027 to 0.0034 are obtained in all the micelle samples for 72 h incubation (IC_{50} of intact ADR was 0.0039). These facts suggested that only the physically entrapped ADR expressed cytotoxic activity, while the chemically conjugated ADR did not for the incubation periods up to 72 h. However, the chemically conjugated ADR might express cytotoxic activity in vivo where the polymeric micelle could reside at tumor sites for a longer period than 72 h.

4. Discussion

Large enhancement of antitumor activity of ADR was successfully achieved by its incorporation into polymeric micelles with the controlled amounts of the chemically conjugated and physically entrapped ADR. The high in vivo antitumor activity of run 1 is considered to result from selective delivery of the physically entrapped ADR to solid tumor sites, since the block copolymer-drug conjugate run A did not show any in vivo activity. Furthermore, in vivo antitumor activity was found to depend on contents of the physically entrapped and chemically conjugated ADR; run 1 showed the activity, and run 2 and 3 did not. Gel-filtration analyses revealed differences in micelle structural stability. The polymeric micelle with high structural stability shown by a small

Fig. 6. In vivo antitumor activity of ADR in female mice (6 started). Drug was (a) □: Control, mg/kg, ●: total done by a Dunne

ate that antitumor
DR contents of the

polymeric micelles
cells are summa-
s are shown by the
sically entrapped)
samples expressed
toxicity, and their
ose of intact ADR
When these values
sically entrapped
multiplied values are
ntact ADR: values
ined in the three
n A (IC_{50} of intact
0.0027 to 0.0034
samples for 72 h
as 0.0039). These
sically entrapped
while the chemi-
or the incubation
chemically conju-
ic activity in vivo
d reside at tumor

activity of ADR
incorporation into
olled amounts of
sically entrapped
activity of run 1 is
e delivery of the
tumor sites, since
te run A did not
hermore, in vivo
pend on contents
hemically conju-
ity, and run 2 and
vealed differences
polymeric micelle
own by a small




Fig. 6. In vivo antitumor activity of ADR and polymeric micelles against C 26. (a) ADR, (b) run A, (c) run 1, (d) run 2, and (e) run 3. CDF₁ female mice (6 weeks old) were subcutaneously transplanted with C 26 cells. Eight days after the tumor transplantation, drug injection started. Drug was injected intravenously three times on day 0, 4, and 8. Data with four or less surviving mice are not plotted. Plot symbols; (a) \square : Control, \bullet : ADR 20 mg/kg, \bullet : ADR 10 mg/kg, \circ : ADR 5 mg/kg, \circ : ADR 2.5 mg/kg, (b)–(e) \square : Control, \bullet : total ADR 100 mg/kg, \bullet : total ADR 50 mg/kg, \circ : total ADR 25 mg/kg, \circ : total ADR 12.5 mg/kg, and \diamond : total ADR 6.3 mg/kg. Statistical analysis was done by a Dunnett's method on day 10; *** $p < 0.05$, ** $p < 0.1$, and * $p < 0.15$.

Table 4

In vitro cytotoxicity of polymeric micelles against P388D1.

sample	IC ₅₀ (ADR equivalents $\mu\text{g/ml}$) ^a	
	24 h incubation ^b	72 h incubation ^b
run A	n.d. ^c	0.57
run 1	0.92	0.017
run 2	2.3	0.032
run 3	1.6	0.033
ADR	0.17	0.0039

^aIC₅₀ values are shown by the total (chemical conjugated and physical entrapped) ADR.^bInitial cell concentration: 24 h incubation; 7.8×10^5 cells/ml, 72 h incubation 4.3×10^5 cells/ml.^cn.d.; not detected up to 118 $\mu\text{g/ml}$.

elution volume expressed high in vivo antitumor activity. These results indicate that stable physical entrapment of ADR was essential for in vivo antitumor activity in this polymeric micelle drug carrier system.

In our preceding report [9], polymeric micelles were found to selectively accumulate at C26 tumors by radioisotope label on block copolymers. This selectivity was considered to be based on hyperpermeability of the vascular endothelia at tumor sites [20,21]. This unique phenomenon was clearly defined as enhanced permeability and retention effect (EPR effect) for a drug targeting strategy to solid tumors [22,23]. Although this EPR effect was originally reported for proteins such as albumin, it may be applied also to polymeric micelles that have much larger diameters than those of the proteins. In order to utilize the EPR effect for drug targeting to solid tumors, interactions (e.g. hydrophobic interactions) of drug carrier systems with the vascular endothelial cells should be avoided, since these hydrophobic interactions may considerably reduce contribution of diffusive and convectional transport (through intracellular channels or intercellular junctions of endothelia) on which the EPR effect is based. The polymeric micelles with the PEG outer shells are considered to inherently possess selective targeting ability to tumors by the EPR effect, since PEG is known to be an inert polymer with very small interactions with cells and proteins, as demonstrated by prolongation of plasma half-lives of several proteins by PEG modification [24,25]. Stability of the polymeric micelles measured by gel-filtration

chromatography is considered to show how completely the hydrophobic inner cores were shielded by the PEG outer shells. Consequently, the stable polymeric micelles could more effectively utilize the EPR effect by more efficiently inhibiting the hydrophobic interactions. To obtain the stable entrapment, large amounts of the chemically conjugated and physically entrapped of ADR were required probably for tight packing of the hydrophobic inner cores.

It is considered that the chemically conjugated ADR did not play a major role in antitumor activity, since polymeric micelle run A did not show any in vivo activity and did show no or low in vitro cytotoxic activity. Such no or low activities are considered to result from no or slow (if any) release of free ADR from the block copolymer due to the absence of cleavable spacer groups such as tetrapeptide of Kopecek's study [2]. However, it still remains unknown whether the chemically conjugated ADR could express any pharmacological effects or not. According to Tritton's study [26], the conjugated ADR can express cytotoxic activities without any release of free ADR. Further studies will be done to clarify this point. On the other hand, the chemically conjugated ADR was shown to contribute to physically entrap free (unconjugated) ADR in a stable manner inside the inner core, since no physical entrapment of ADR was attained by mixing ADR and poly(ethylene glycol)-poly(aspartic acid) block copolymer (data not shown). Martin et al. [27] reported self-association of daunomycin (an adriamycin analogue). Therefore, the conjugated ADR is considered to work as a very good carrier of the physically entrapped ADR by providing specific interactions (e.g. π - π interaction) between the two ADR molecules as well as non-specific hydrophobic interactions.

A dimer was found to form during the physical entrapment of ADR for run 1. The content of this dimer (8.6% out of the total ADR, obtained from its peak area in Fig. 2c in the polymeric micelle run 1 was smaller than that of ADR (17.8%). There are several possibilities for roles of this dimer in antitumor activity in vivo. The first one is that the dimer does not possess any particular significance on antitumor activity or selective delivery. In other words, antitumor activity and selective delivery only depend on a total quantity of the physically en-

trapped ADR. However, is unlikely hydrophobicity other hand, the in vivo activity different from ADR, with volume in run ADR. The different possible ways; important role in ADR by more its smaller release stream, (2) The ADR, which plays at tumor sites. to elucidate the

References

- [1] V.R. Torchilin, Adv. Drug D.
- [2] D. Patnum, J. activity, Adv.
- [3] T.M. Allen, A. uptake into t. (1987) 42–44.
- [4] D.D. Lasic, Papahadjopoulos on the times, Biochim.
- [5] S. Stolin, L. tulate drug 195–214.
- [6] M. Yokoyama, Shibasaki, K. against solid drug and its e 51 (1991) 32.
- [7] A.V. Kabanov, Fedoseev, T.I. Nazarova, V. micelles of p polymers as r brain, J. Con.
- [8] A. Rolland, Petrak, New tion and cha oxyethylene) Sci. 44 (1992).
- [9] G.S. Kwon, K. Kataoka, circulation ti

trapped ADR and this dimer. This hypothesis, however, is unlikely because of significant difference in hydrophobicity between the dimer and ADR. On the other hand, this dimer may be important for the in vivo activity due to its more hydrophobic character than ADR, which was shown by its larger elution volume in reversed-phase chromatography than ADR. The dimer can work in the following two possible ways; (1) the dimer played a more important role in cytotoxic activity at tumor sites than ADR by more efficient delivery to tumor sites due to its smaller release from the micelles in the bloodstream, (2) The dimer contributed to stably entrap ADR, which played a major role in cytotoxic activity at tumor sites. Further study is currently under way to elucidate these points.

References

- [1] V.R. Torchilin (Ed.), Long-circulating drug delivery systems, *Adv. Drug Deliv. Rev.*, 16, nos. 2, 3, 1995.
- [2] D. Patum, J. Kopecek, Polymer conjugates with anticancer activity, *Adv. Polymer Sci.* 122 (1995) 55–123.
- [3] T.M. Allen, A. Chonn, Large unilamellar liposomes with low uptake into the reticuloendothelial system, *FEBS Lett.* 223 (1987) 42–46.
- [4] D.D. Lasic, F.J. Martin, A. Gabizon, S.K. Huang, D. Papahadjopoulos, Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times, *Biochim. Biophys. Acta* 1070 (1991) 187–192.
- [5] S. Stolnik, L. Illum, S.S. Davis, Long circulating microparticulate drug carriers, *Adv. Drug Deliv. Rev.* 16 (1995) 195–214.
- [6] M. Yokoyama, T. Okano, Y. Sakurai, H. Ekimoto, C. Shibazaki, K. Kataoka, Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood, *Cancer Res.* 51 (1991) 3229–3236.
- [7] A.V. Kabanov, E.V. Batrakova, N.S. Melik-Nubarov, N.A. Fedoseev, T.Y. Dorodnich, V.Y. Alakhov, V.P. Chekhonin, I.R. Nazarova, V.A. Kabanov, A new class of drug carriers: micelles of poly(oxyethylene)-poly(oxypropylene) block copolymers as microcontainers for drug targeting from blood in brain, *J. Control. Release* 22 (1992) 141–158.
- [8] A. Rolland, J. O'mullane, P. Goddard, L. Brookman, K. Petrak, New macromolecular carriers for drugs. I. Preparation and characterization of poly(oxyethylene-b-isoprene-b-oxyethylene) block copolymer aggregates, *J. Appl. Polym. Sci.* 44 (1992) 1195–1203.
- [9] G.S. Kwon, S. Suwa, M. Yokoyama, T. Okano, S. Sakurai, K. Kataoka, Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly(ethylene oxide-aspartate) block copolymer-adriamycin conjugates, *J. Control. Release* 29 (1994) 17–23.
- [10] M. Yokoyama, S. Inoue, K. Kataoka, N. Yui, T. Okano, Y. Sakurai, Molecular design for missile drug: Synthesis of adriamycin conjugated with immunoglobulin G using poly(ethylene glycol)-block-poly(aspartic acid) as intermediate carrier, *Makromol. Chem.* 190 (1989) 2041–2054.
- [11] A.V. Kabanov, V.P. Chekhonin, V.Y. Alakhov, E.V. Batrakova, A.S. Lebedev, N.S. Melik-Nubarov, S.A. Arzhakov, A.V. Levashov, G.V. Morozov, E.S. Severin, V.A. Kabanov, The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles: micelles as microcontainers for drug targeting, *FEBS Lett.* 2 (1989) 343–345.
- [12] M. Yokoyama, G.S. Kwon, T. Okano, Y. Sakurai, H. Ekimoto, K. Okamoto, H. Mashiba, T. Seto, K. Kataoka, Composition-dependent in vivo antitumor activity of adriamycin-conjugated polymeric micelle against murine colon adenocarcinoma 26, *Drug Del.* 1 (1993) 11–19.
- [13] M. Yokoyama, Block copolymers as drug carriers, *Crit. Rev. Ther. Drug Carrier Syst.* 9 (1992) 213–248.
- [14] M. Yokoyama, Site specific drug delivery using polymeric carriers, in: *Advances in Polymeric Systems for Drug Delivery*, Gordon and Breach Science Publishers, Yverdon, Switzerland, 1994, pp. 24–66.
- [15] G.S. Kwon, M. Naito, K. Kataoka, M. Yokoyama, Y. Sakurai, T. Okano, Block copolymer micelles as vehicles for hydrophobic drugs, *Colloids and Surfaces B: Biointerfaces* 2 (1994) 429–434.
- [16] M. Yokoyama, G.S. Kwon, T. Okano, Y. Sakurai, T. Seto, K. Kataoka, Preparation of micelle-forming polymer-drug conjugates, *Bioconjugate Chem.* 3 (1992) 295–301.
- [17] M. Yokoyama, T. Okano, Y. Sakurai, K. Kataoka, Improved synthesis of adriamycin-conjugated poly(ethylene oxide)-poly(aspartic acid) block copolymer and formation of unimodal micellar structure with controlled amount of physically entrapped adriamycin, *J. Control. Release* 32 (1994) 269–277.
- [18] T. Mosmann, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays, *J. Immunol. Methods* 65 (1983) 55–63.
- [19] M. Yokoyama, T. Sugiyama, T. Okano, Y. Sakurai, M. Naito, K. Kataoka, Analysis of micelle formation of adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer by gel-permeation chromatography, *Pharm. Res.* 10 (1993) 895–899.
- [20] H.F. Dvorak, N.S. Orenstein, A.C. Carvalho, W.H. Churchill, A.M. Dvorak, S.J. Galli, J. Feder, A.M. Bitzer, J. Rypysc, P. Giovenco, Induction of a fibrin-gel investment: An early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products, *J. Immunol.* 122 (1979) 166–174.
- [21] H.F. Dvorak, F.B. Lawrence, M. Detmar, A.M. Dvorak, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis, *Am. J. Pathol.* 146 (1995) 1029–1039.
- [22] Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumorotropic accumulation of proteins and the antitumor agent smancs, *Cancer Res.* 46 (1986) 6387–6392.

- [23] H. Maeda, L.W. Seymour, Y. Miyamoto, Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. *Bioconjugate Chem.* 3 (1992) 351–362.
- [24] A. Abchowski, J.R. McCoy, N.C. Palczuk, T. van Es, F.F. Davis, Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. *J. Biol. Chem.* 252 (1977) 3582–3586.
- [25] N.V. Katre, M.J. Knauf, W.J. Laird, Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. *Proc. Natl. Acad. Sci., USA* 84 (1987) 1487–1491.
- [26] L.B. Wingard Jr., T.R. Tritton, K.A. Egler, Cell surface effect of adriamycin and carminomycin immobilized on cross-linked polyvinyl alcohol. *Cancer Res.* 45 (1985) 3529–3536.
- [27] S.R. Martin, Absorption and circular dichroic spectral studies in the self-association of daunomycin. *Biopolymers* 19 (1980) 713–721.



Antig

Tamn
Departm

Abstract

Several recent s
the most effective
biocompatible, va
Mice were prime
boosted by insert
providing controll
ferritin-specific Ig
poly(lactic acid) r
the presence of ch
vaginal rings, pro
Science B.V.

Keywords: Contr
nology

1. Introduction

According to
least 150 000 u
sexually transmi
worldwide. In s
become even mo

*Corresponding
Engineering, Cornel
USA. Tel.: +1 60
saltzman@cheme.co
Current address:
USA.

0168-3659/98/\$19.4
PII S0168-3659(